Recording – Roundup Webinar | Civil Society Monitoring of Harm Reduction in Europe

 

The video is the recording of the webinar organised to celebrate the core publications for the C-EHRN Civil Society-led Monitoring of Harm Reduction in Europe that took place on the 7th of March.

The event brought together four volumes of the 2023 Data Report:


Moderator:
 Rafaela Rigoni (C-EHRN)

Speakers:
Iga Jeziorska (C-EHRN) – Essential Harm Reduction Services
Tuukka Tammi (THL) – Eliminating Hepatitis C in Europe
Daan van der Gouwe (Trimbos) – New Drug Trends
Guy Jones (TEDI) – Drug Checking Observations and European Drug Checking Trends via TEDI

 
Following a new format, Correlation – European Harm Reduction Network’s Civil Society-led Monitoring of Harm Reduction in Europe 2023 Data Report is launched in 6 volumes: Hepatitis C CareEssential Harm Reduction ServicesNew Drug TrendsMental Health of Harm Reduction StaffTEDI Reports and City Reports (WarsawBălţiEsch-sur-AlzetteLondonAmsterdam). The Executive Summary can be accessed here.

Drug Checking Observations and European Drug Checking Trends via TEDI

To monitor new drug trends in Europe and complement the information gained through focus group discussions, C-EHRN’s 2023 Civil Society-led Monitoring of Harm Reduction in Europe includes two reports via the Trans European Drug Information Network (TEDI), drawing from data collected from drug checking services.

The snapshot report contains information from the first two quarters of 2023 for each drug where significant drug checking data exists in Europe. These are amphetamine, cocaine, ketamine, MDMA, methamphetamine, heroin, and general pages for benzodiazepine sedatives, novel stimulants and novel opioids. The multi-year report contains data since 2018 and aims to show the changes in drug markets over time.

Download the snapshot report and the multi-year report and read the interview with Guy Jones, TEDI’s data manager and the primary author below!

How do you see the role of drug-checking services?

Drug checking services are an invaluable tool that are able to both monitor trends while also responding in real-time to mitigate the health impacts that emerging trends may have. They have unique insight into new trends as they can talk directly to service users to understand the real drivers of new consumption patterns and understand whether people are deliberately seeking out a new drug or if it is simply being added by manufacturers.

 

What are the main adulterants and risk trends in the European drug market based on the data you 

analysed from 2023?

2023 has seen the market recover to pre-COVID trends of increasing strength of some drugs, presenting a significant risk that service users regularly underestimate.

Alongside this, there is major concern about the potential for changes in the heroin supply from Afghanistan and whether this could lead to a move to synthetic opioids as was seen in North America over the last decade.

 

Would you highlight any differences in drug preferences in the past year between European countries based on the findings?

Not really. Europe has a fairly consistent supply throughout the continent, however, there are consumption patterns that exist more in certain countries, such as a slightly higher prevalence of amphetamine in Eastern Europe.

 

Based on the data you analysed, what are the most significant changes in the drug markets over time?

When I first started working in the field, I never expected that we would find ourselves in a position where the major threat in the cocaine supply was because it was so strong and unadulterated.

 

How do you think harm reduction organisations can use the reports?

The reports are often extremely interesting to service users and they can serve as an invaluable starting point for discussions about risk from adulteration but also about the role that tolerance plays in a service user’s experience of a drug.

 

How do you think data from drug-checking services can be combined with other kinds of research, such as the data from insights from focus group discussions conducted as part of C-EHRN’s 2023 Civil Society-led Monitoring of Harm Reduction in Europe?

Data is extremely useful for “calibrating” qualitative observations to help us understand whether they are accurate reflections of reality and tuning how we collect qualitative data to get more accurate information, faster.

 

Would you pick a graph that you find significant and explain why you find it relevant?

Not a chart, but a number from the snapshot report. The median heroin sample contains just 17% purity, with huge variation. This variation already creates a risk for people who use heroin but it also means that organised groups wouldn’t have much to do to create a product that is much stronger and substitutes heroin for synthetic opioids. Experience shows us that law enforcement won’t reduce the health risk from this.

 
 

Following a new format, Correlation – European Harm Reduction Network’s Civil Society-led Monitoring of Harm Reduction in Europe 2023 Data Report is launched in 6 volumes: Hepatitis C CareEssential Harm Reduction ServicesNew Drug TrendsMental Health of Harm Reduction StaffTEDI Reports and City Reports (WarsawBălţiEsch-sur-AlzetteLondonAmsterdam). The Executive Summary can be accessed here.

Executive Summary | Civil Society-led Monitoring of Harm Reduction in Europe 2023

Following a new format, Correlation – European Harm Reduction Network’s Civil Society-led Monitoring of Harm Reduction in Europe 2023 Data Report is launched in 6 volumes: Hepatitis C CareEssential Harm Reduction ServicesNew Drug TrendsMental Health of Harm Reduction StaffTEDI Reports and City Reports (WarsawBălţiEsch-sur-AlzetteLondonAmsterdam). 

Roundup Webinar | Civil Society-led Monitoring of Harm Reduction in Europe

To celebrate the core publications for the C-EHRN Civil Society-led Monitoring of Harm Reduction in Europe, we invite you to join the roundup webinar on the 7th of March, 1:00 PM (CET)!

 
The event will bring together four recently published volumes of the 2023 Data Report:
 
During the interactive webinar, the primary authors of each publication will join  Rafaela Rigoni, C-EHRN’s Head of Research, to debate positive developments and the main advocacy asks arising from the reports’ conclusions. We’ll invite participants to interact via a Q&A session.
 
Moderator:
Rafaela Rigoni (C-EHRN)
 
Speakers:
Iga Jeziorska (C-EHRN) –  Essential Harm Reduction Services
Tuukka Tammi (THL) –  Eliminating Hepatitis C in Europe
Daan van der Gouwe (Trimbos) – New Drug Trends
Guy Jones (TEDI) – Drug Checking Observations and European Drug Checking Trends via TEDI

To join the webinar, register by the 6th of March on this link!

 

Following a new format, Correlation – European Harm Reduction Network’s Civil Society-led Monitoring of Harm Reduction in Europe 2023 Data Report is launched in 6 volumes: Hepatitis C CareEssential Harm Reduction ServicesNew Drug TrendsMental Health of Harm Reduction StaffTEDI Reports and City Reports (WarsawBălţiEsch-sur-AlzetteLondonAmsterdam). The Executive Summary can be accessed here.

New Drug Trends: Insights from Focus Group Discussions

We are launching our publication New Drug Trends: Insights from Focus Group Discussions, part of Correlation – European Harm Reduction Network’s Civil Society-led Monitoring of Harm Reduction In Europe 2023 Data Report.

The study relies on 18 focal group discussions conducted among civil society organisations designated as focal points within the Network and explores the latest insights concerning the emergence of new illicit substances in cities where focal points are located, as well as other developments in drug use patterns, including polydrug use, routes of administration, and changes in local drug markets.

We bring an interview with Daan Van der Gouwe, primary author, researcher at Trimbos Institute and coordinator of the Dutch Harm Reduction Network. Read the interview and download the publication below!

Which main developments would you highlight when it comes to new or unknown substances compared to last year’s report?

We have witnessed a number of developments this year. When we look at the community of people who are engaged in high-risk drug use, we see the appearance of various synthetic opioids in heroin or benzodiazepines, for instance, nitazenes, but fentanyls are also gaining ground in some areas in Europe. With nitazenes, it seems to be geographically limited still in the northwestern part of Europe, mainly in Ireland and the UK. Whereas when it comes to fentanyls that are found in heroin,  we see it in other areas of Europe. This is the main finding that we didn’t see so much last year.

Within the group of people with high-risk drug use, we also see an increa

se in the use of cocaine and methamphetamine. This cocaine includes crack cocaine, especially.

People also spoke about the ban on opium cultivation by the Taliban in 2023, that this should have an effect on the heroin market, but we don’t see that very clearly at the moment. Heroin is still available but it may be the case that this year, in 2024, it will be a different situation.

When it comes to recreational drug use, we do not see so much difference. We see some appearance of 2C-B, ketamine, some cathinones and especially also cocaine being more present on local drug markets in Europe.

 

The findings show that the internet takes up an increasing space in the sale of drugs. Are there any recommendations or best practices on how harm reduction services can respond to this?

Yes, this is a clear finding. We have witnessed this feature for several years already, but last year it was really strong. I’d like to make a plea for harm reduction NGOs to go online and inform themselves about the changing markets, to see what’s going on online, but also to start some interventions there and to do internet-based harm reduction, for instance, online outreach work.

We have had a pioneer, his name is Fernando Caudevilla, DoctorX, who did this work already 10-15 years ago. He did that on the darknet, he answered questions of people who use drugs, and he gave very proper harm reduction advice to anyone who had questions about drug use. Maybe in some countries like the Netherlands, we have this clear-cut information everywhere online, but in many other countries, for instance, in Russia, this information is not available.

This kind of work, online harm reduction services are essential for people to take note of. This would be a very important thing to do and to start conducting.

 

Would you pick a quote from the report that you find significant and explain why you find it relevant?

I’d like to quote the focal point in Glasgow in the UK, Scotland:

“(…) There are few reports to corroborate (the use of nitazenes), but (…seem to be….) people who have reported long term use of other drugs and have purchased as heroin.” (p. 13.)

I think this quote is a good example of where we are nowadays. We have a number of reports on nitazenes and other synthetic opioids in heroin, but the evidence is lagging behind, particularly because there’s a lack of drug checking services in the European Union or globally. So people do not really know what they are buying and using. This is why it’s very important to have drug checking services so that when people purchase heroin, they could find out that this ‘heroin’ contains no heroin, or contains heroin but also nitazenes, which are much stronger and can be lethal. So it’s essential to have these services all around the globe.

 

How do you think harm reduction organizations can use the report?

The report can be used as an advocacy tool, to advocate for a better early warning system, especially since now drug markets are more polluted. Look at the heroin market, but some other markets also seem to be more polluted. Also because drug markets continue to go online.

Harm reduction services also need to find funding for better services and for better serving the needs of people who use stimulant drugs, especially crack and methamphetamine, since we have seen an increase in crack and methamphetamine on the market and services for these users are also lagging behind.

This report clearly identifies these developments which are in line with data from, for instance, the EMCDDA [European Monitoring Centre for Drugs and Drug Addiction]. It would be good that harm reduction services use the report and the recommendations to get access to additional funding to serve the people they’re working for in a better way.

 

Qualitative data is a significant complementary source to gain information, and as you mentioned, there seem to be limitations when it comes to gaining information about the quality or composition of substances, and that’s where drug checking can be very important. How do you think research methods can be combined in the best way and what do you think is necessary for this to happen?

What I think is necessary to develop further is that we look at different sources. In the scientific world, we call it triangulation of data. It means that we use data from the focus groups that we have been conducting for many years now in the framework of Correlation to compare those data with the drug checking data from several cities. But also, I think wastewater analysis could be a very interesting tool. Also, there’s a project going on which identifies and detects drugs in syringes.

I think with all those different sources together we can quickly see trends and developments in the drug markets. Also, what is even more important than just detecting or identifying is to intervene as quickly as possible.

For instance, this situation with nitazenes, it’s very worrying in a specific part of Europe now, but it could extend to the whole of Europe quickly. Then it also needs to be responded to in a very quick and precise manner. The data we get, along with all the other data, for instance from drug checking, could help to do so.

 

What is the added value of this type of civil society-led monitoring with focal group discussions in comparison with the other types of monitoring of drug trends that are already done by major monitoring agencies?

The added value of the work that we do within the framework of Correlation is that we can get much richer data across than just the valuable data that are being collected by other agencies. They also take some time for publications, which means the day they are published, the data is rather old. We have developed now a system in which we can publish our data in a bit quicker way, which also means that we can intervene more quickly.

The other value is that we can put more layers of information of context in the data that are provided by other services, for instance, about drug markets. As an example, besides the internet-based drug markets that are now emerging, in some focus group discussions, there was a mention of increasing violence in the drug markets. Violence between drug dealers, violence between people who use drugs, violence between people who use drugs and drug dealers, and also violence between people who use drugs, drug dealers and the largest society. It seems that in some cities this violence is becoming more apparent than before, and this is also something we need to address.

 

What do you think the most urgent steps are that need to be done at the European level?

Two things I’ve already mentioned are the expansion of drug checking services throughout Europe, and also the expansion of harm reduction online.

Since there’s an increase in the appearance and use of stimulant drugs, especially crack cocaine and methamphetamine, but also some cathinones, harm reduction services should step up in delivering services that address the people using these stimulants.

Finally, there’s a need for preparedness for the changing heroin markets.  As I said before, we see that the heroin market is increasingly polluted with fentanyls, but also in some areas with nitazines, and we believe that harm reduction services throughout Europe should prepare themselves in the best possible way to respond to the crisis that may emerge in the coming years.

 

Following a new format, Correlation – European Harm Reduction Network’s Civil Society-led Monitoring of Harm Reduction in Europe 2023 Data Report is launched in 6 volumes: Hepatitis C CareEssential Harm Reduction ServicesNew Drug TrendsMental Health of Harm Reduction StaffTEDI Reports and City Reports (WarsawBălţiEsch-sur-AlzetteLondonAmsterdam). The Executive Summary can be accessed here.

 

DRUG-PREP update: Research on the current drug landscape to be published soon

Research on the growing complexity of the current drug landscape was carried out during the course of last year as part of the DRUG-PREP project led by the Trimbos Institute and 6 European partners, the results of which will soon be published.

The objective of the research project was to assess the current European situation regarding drug-related developments and emerging threats. It also aimed to identify recommendations and best practices that can enhance the preparedness of drug information systems, threat assessment and response interventions. Methodologies included desk research and literature reviews, questionnaires submitted to the EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) Reitox National Focal Points, in-depth interviews with 30 key experts, and qualitative and thematic analysis.

Results from the literature review, desk research and questionnaires show an increase in drug use in Europe in the last two years, specifically in crack cocaine, methamphetamine, nitrous oxide, the emergence of off-label medicine use, especially (counterfeit) benzodiazepines and of polysubstance use, or the use of several drugs simultaneously.

Furthermore, developments in the drug market have been noted, such as larger availability and purity of cocaine together with its decrease in price, changes in cannabis prices and usage of synthetic cannabinoids, and adulteration of “traditional” drugs with different new psychoactive substances. The drug trade through online markets and social media is also on the rise. Other phenomena, such as a renewed use of crack cocaine, use of GHB/GBL, synthetic opioids and changes in administration routes (vaping, smoking, inhalation) have been observed especially within more marginalised communities. Another finding is that a larger number of harm reduction services are available in Europe, including DCRs, Naloxone provision and low-threshold integrated services.

From the in-depth interviews with key experts, it was concluded that staying prepared for new, unknown or unexpected drug-related threats is currently still a challenge at both the national and European levels. Other issues include the slowness of monitoring and surveillance tools combined with difficulties in delivering monitoring results to policymakers and successfully translating them into policy.

To counter these problems it would be good to innovate monitoring tools and complement them with foresight activities, including a larger number of individuals, field practitioners and stakeholders in trend detection, and investing in the coordination and formalisation of national threat assessment and information exchange systems. Lastly, it would be necessary to ensure that monitoring results are delivered to target audiences and decision-makers, that effective response protocols are formalised, and that responses are strategic, coherent and inclusive of a broader range of stakeholders on the regional and European level.

 

The full report on this research activity will soon be available on the DRUG-PREP project’s website.